DENTSPLY SIRONA (XRAY) Q4 2021 earnings summary

Executive summary

• FY 2021 results rebounded with demand recovery: net sales rose 27.2% reported and 24.6% organically; strategic priorities remained growth, margin expansion, and organizational simplification.

• Strategy centers on integrated digital workflows across implants, orthodontics, endodontics, and restorative dentistry, supported by higher R&D investment, product launches, and acquisitions.

• Restructuring and portfolio optimization have delivered more than 500 bps of operating margin expansion since 2018, while funding R&D and demand-generation investments.

Financial highlights

• Net sales were $4.251B versus $3.342B in 2020; reported growth was 27.2%, organic growth 24.6%, and favorable FX contributed 2.9%.

• Net income was $421M versus a net loss of $83M; operating income was $622M versus a $12M loss, with 2020 including a $157M goodwill impairment.

• Cash from operations was $657M versus $635M; gross profit rose 42.5% to $2.361B.

• Adjusted for acquisitions, divestitures, discontinued products, and FX, organic sales increased 24.6% for FY 2021.

Outlook and guidance

• Restructuring targets annualized net sales growth of 4%-5% and adjusted operating income margin of 22% by Q4 2022; annual cost savings target is ~$250M, with total program charges of ~$345M.

• 2022 capital expenditures are estimated at $150M-$170M, including facility expansion and consolidation investments.

• R&D investment is expected to remain at least 4% of annual net sales; continued growth investment and further margin expansion remain priorities.

• Strategy includes developing a digital platform with Google Cloud and continuing to consider acquisitions aligned with growth priorities.